NCT02204332终止2 期
Phase II-b Randomized Study of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 38
- 试验地点
- 8
- 主要终点
- The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.
研究概览
简要总结
The purpose of this study is to determine efficacy and safety of cabazitaxel administration in patients with colorectal cancer resistant to standard treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have given written informed consent.
- •Men and women aged ≥ 18 years.
- •Patients with histologically confirmed metastatic advanced colorectal cancer without the possibility of potentially curative treatment.
- •Patients with a life expectancy more than three months.
- •Patients with advanced colorectal cancer in progression after receiving standard treatment.
- •Patients with grade 0-2 functional status, according to Eastern Cooperative Oncology Group (ECOG).
- •Patients with evaluable tumor by RECIST criteria.
- •Patients recovered and with a degree less than or equal to 1, or baseline of all important pre-treatment-related AEs (excluding alopecia).
- •Ability and willingness of the patient to consent to participation in the study.
- •Ability to understand and comply with study procedures.
排除标准
- •Patients with a performance status greater than 2, as Eastern Cooperative Oncology Group (ECOG).
- •Inadequate marrow reserve, within 7 days prior to randomization:
- •absolute neutrophil count <1.5 x 109 / L
- •Hemoglobin <9.0 g / dL
- •Platelet count <100 x 109 / L
- •Inadequate liver function within 7 days prior to randomization:
- •AST (SGOT) and ALT (SGPT)> 3.0 x ULN or 5> x ULN in case of abnormal liver function due to underlying liver metastases.
- •Alkaline phosphatase> 3 × ULN (or 5 times the ULN if due to underlying liver metastases).
- •Total bilirubin> 1.5 x ULN.
- •Previous history of other malignancy, except for skin basal or squamous cell cancer with proper treatment, or in situ cervical cancer, or other cancers, in which the patient has been free of the disease in the last 5 years.
- •Simultaneous treatment with concomitant anticancer therapy.
- •History of brain metastases, uncontrolled compression of spinal cord, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease pathologies.
- •Acquired Immunodeficiency Syndrome (AIDS-related diseases) or human immunodeficiency virus (HIV) or conditions requiring antiretroviral therapy virus.
- •symptomatic grade ≥ 2 peripheral sensory neuropathy, according to NCI-CTCAE v4.
- •Any severe acute or chronic medical condition that may affect the patient's ability to participate in the study, or may lead to unacceptable security risks and non-compliance with protocol procedures or may interfere with the interpretation of the study results.
- •Pregnant women or who are breastfeeding. Pregnancy assessment will be conducted by a test serum or urine during the 7 days prior to randomization.
- •Patient (male or female) of reproductive age who still disagrees with the use of effective contraception during the treatment period and for at least 3 months after completion of the treatment period of the study. The definition of "effective method of birth control" is the opinion of the investigator.
- •Participation in another clinical trial with an investigational drug and / or an investigational drug as adjunctive therapy within 30 days prior to randomization.
- •Concomitant treatment with prohibited drugs as potent inhibitors or inducers of cytochrome P450 3A4.
研究组 & 干预措施
Cabazitaxel
Experimental
Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).
Besides, patient will be treated with BSC.
干预措施: Cabazitaxel (Drug)
Best Supportive Care
Other
Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
干预措施: Best Supportive Care (Other)
结局指标
主要结局
The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.
时间窗: From date of randomization to disease progression or until 24 months from enrolment
次要结局
- Progression-free survival (PFS)(From randomisation to either documented disease progression or death from any cause or until 24 months from enrolment (whichever occurs earlier))
研究者
Rafael Lopez Lopez
MD,PhD
Hospital Clinico Universitario de Santiago
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With TaxanesBreast CancerNCT01693549Hellenic Cooperative Oncology Group84
已完成
2 期
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Head and NeckNCT01528163Cliniques universitaires Saint-Luc- Université Catholique de Louvain101
进行中（未招募）
不适用
Study to assess the efficacy of the drug Cabazitaxel in patients with Metastatic Colorectal Cancer.Metastatic colorectal cancer resistant to standard treatment.MedDRA version: 14.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001218-32-ESRafael López López
已完成
2 期
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung CancerSmall Cell Lung CancerNCT01500720Sanofi179
终止
2 期
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo RegimenEsophagealGastrooesophageal CancerGastric CancerNCT01365130howard safran15